Abstract
Recently, two independent genome-wide association studies (GWAS) have identified CD33 gene, encoding cluster of differentiation 33 (CD33), as a genetic locus associated with Alzheimer's disease (AD). It has been suggested that CD33 may contribute to AD pathogenesis by involving in inflammatory response, synaptic dysfunction and cell membrane processes. We analyzed the expressions of CD33 in peripheral blood mononuclear cells (PBMCs) in AD group and control group by real-time quantitative polymerase chain reaction and flow cytometry. Expression of CD33 mRNA was down-regulated in AD patients comparing to controls (p=0.001). The frequency of CD33 positive monocytes was also lower in AD patients than in controls (44.02±22.17% versus 54.06±21.86%, p=0.001). Moreover, we observed a correlation between CD33 positive monocytes levels and Mini Mental State Examination (MMSE) score (r=0.220, p<0.05). According to receiver operating characteristic (ROC) curve analysis, the diagnostic accuracy for CD33 alone is relatively lower, while, combining with additional parameters might further improve the diagnostic value for AD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
